402 related articles for article (PubMed ID: 17699372)
1. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
2. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
3. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
Zager RA
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
5. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
6. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
7. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
9. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
10. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
12. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
13. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
14. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
15. Should intravenous iron be upfront therapy for iron deficiency anemia?
Auerbach M
Pediatr Blood Cancer; 2011 Apr; 56(4):511-2. PubMed ID: 21298731
[No Abstract] [Full Text] [Related]
16. Comparative rates of adverse events with different formulations of intravenous iron.
Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
18. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
19. Parenteral iron therapy options.
Silverstein SB; Rodgers GM
Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]